Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: Systematic review

Clinical Journal of Pain

Volumn 28, Issue 5, 2012, Pages 437-451

  Häuser, Winfried ^a,b   Bartram, Claas ^a,b   Bartram Wunn, Eva ^a,b   Tölle, Thomas ^b  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

fibromyalgia syndrome; meta analysis; nocebo; painful diabetic peripheral neuropathy; systematic review

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; ANALGESIC AGENT; CITALOPRAM; CYCLOBENZAPRINE; DOSULEPIN; DULOXETINE; GABAPENTIN; GROWTH HORMONE; HOMEOPATHIC AGENT; MILNACIPRAN; MISCELLANEOUS DRUGS AND AGENTS; MYER COCKTAIL; NOCEBO; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PREGABALIN; REBOXETINE; ROPINIROLE; STAPHYLOCOCCUS TOXOID; TERGURIDE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DRUG DOSE INCREASE; FIBROMYALGIA; HUMAN; NOCEBO EFFECT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; ANALGESICS; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUG INDUSTRY; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PAIN MEASUREMENT; PLACEBO EFFECT; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84861100206     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3182321ad8     Document Type: Review

References (27)

1. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006;166:155-160.
2. Sheftell FD, Feleppa M, Tepper SJ, et al. Assessment of adverse events associated with triptans-methods of assessment influence the results. Headache. 2004;44:978-982.
3. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816-828.
4. Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622-627.
5. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron. 2008;59:195-206.
6. Macedo A, Banos JE, Farre M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain. 2008;2:68-75.
7. Amanzio M, Corazzini LL, Vase L, et al. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146:261-269.
8. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211-218.
9. Häuser W, Zimmer C, Felde E, et al. What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz. 2008;22:176-183.
10. Rief W, Barsky AJ, Glombiewski JA, et al. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20:405-415.
11. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and metaanalysis. Drug Saf. 2009;32:1041-1056.
12. Moher D, Liberati A, Teztlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Int Med. 2009;51:1-7.
13. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1. 2011; www.cochrane.org/resources/handbook/handbook. pdf.
14. National Institute for Health and Clinical Excellence. Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings. 2010; www.nice.org. uk/guidance/CG96.
15. Häuser W, Eich W, HerrmannM, et al. Fibromyalgia syndrome: classification, diagnosis, and treatment. Dtsch Arztebl Int. 2009; 106:383-391.
16. Häuser W, Bartram-Wunn E, Bartram C, et al. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain. 2011. [Epub ahead of print].
17. Staud R, Price DD. Importance of measuring placebo factors in complex clinical trials. Pain. 2008;138:474.
18. Quessy SN, Rowbotham MC. Placebo response in neuropathic pain trials. Pain. 2008;138:479-483.
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
20. Häuser W, Petzke F, Üceyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with metaanalysis. Rheumatology. 2011;50:532-543.
21. Laird NM, Mostellier F. Some statistical methods for combining experimental results. In J Technol Assess Health Care. 1990;6:5-30.
22. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50: 1088-1101.
24. Lombardi C, Gargioni S, Canonica GW. The nocebo effect during oral challenge in subjects with adverse drug reactions. Eur Ann Allergy Clin Immunol. 2008;40:138-141.
25. Wooten JM. Adverse drug reactions: part I. South Med J. 2010;103:1025-1028.
26. Berlin JA, Santanna J, Schmid CH, et al. Individual patient versus group-level data metaregressions for the investigation of subgroup effects: ecological bias rears its ugly head. Stat Med. 2002;21:371-387.
27. Price DD, Finiss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thoughts. Ann Res Psychol. 2008;9:565-590.